UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis

Critical reviews in oncology/hematology, 2016-04, Vol.100, p.88-98

2016

Volltextzugriff (PDF)

Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma

The New England journal of medicine, 2020-09, Vol.383 (12), p.1139-1148

2020

Volltextzugriff (PDF)

Targeting the PD1/PD-L1 axis in melanoma: Biological rationale, clinical challenges and opportunities

Critical reviews in oncology/hematology, 2014-01, Vol.89 (1), p.140-165

2014

Volltextzugriff (PDF)

Wnt/β-catenin signaling in melanoma: preclinical rationale and novel therapeutic insights

Cancer treatment reviews, 2016-09, Vol.49, p.1-12

2016

Volltextzugriff (PDF)

Rational combination of cancer immunotherapy in melanoma

Virchows Archiv : an international journal of pathology, 2019-04, Vol.474 (4), p.433-447

2019

Volltextzugriff (PDF)

Dedifferentiated melanomas: Morpho-phenotypic profile, genetic reprogramming and clinical implications

Cancer treatment reviews, 2020-08, Vol.88, p.102060-102060, Article 102060

2020

Volltextzugriff (PDF)

Safety and efficacy evaluation of encorafenib plus binimetinib for the treatment of advanced BRAF-mutant melanoma patients

Expert opinion on drug safety, 2020-10, Vol.19 (10), p.1229-1236

2020

Volltextzugriff (PDF)

Nras in melanoma: Targeting the undruggable target

Critical reviews in oncology/hematology, 2014-11, Vol.92 (2), p.107-122

2014

Volltextzugriff (PDF)

Tissue prognostic biomarkers in primary cutaneous melanoma

Virchows Archiv : an international journal of pathology, 2014-03, Vol.464 (3), p.265-281

2014

Volltextzugriff (PDF)

Targeting BRAF in melanoma: Biological and clinical challenges

Critical reviews in oncology/hematology, 2013-09, Vol.87 (3), p.239-255

2013

Volltextzugriff (PDF)

Molecular Pathways in Melanomagenesis: What We Learned from Next-Generation Sequencing Approaches

Current oncology reports, 2018-11, Vol.20 (11), p.86-16, Article 86

2018

Volltextzugriff (PDF)

Targeting inflamed and non-inflamed melanomas: biological background and clinical challenges

Seminars in cancer biology, 2022-11, Vol.86 (Pt 2), p.477-490

2022

Volltextzugriff (PDF)

Molecular Profiling and Novel Therapeutic Strategies for Mucosal Melanoma: A Comprehensive Review

International journal of molecular sciences, 2021-12, Vol.23 (1), p.147

2021

Volltextzugriff (PDF)

Pathology of Immunotherapy-induced Responses in Cutaneous Melanoma: Current Evidences and Future Perspectives

Advances in anatomic pathology, 2023-05, Vol.30 (3), p.218-229

2023

Volltextzugriff (PDF)

Impact of second opinion pathology review in the diagnosis and management of atypical melanocytic lesions: A prospective study of the Italian Melanoma Intergroup (IMI) and EORTC Melanoma Group

European journal of cancer (1990), 2023-08, Vol.189, p.112921-112921, Article 112921

2023

Volltextzugriff (PDF)

Adjuvant Treatment of Melanoma: Recent Developments and Future Perspectives

American journal of clinical dermatology, 2019-12, Vol.20 (6), p.817-827

2019

Volltextzugriff (PDF)

Impact of Circulating and Tissue Biomarkers in Adjuvant and Neoadjuvant Therapy for High-Risk Melanoma: Ready for Prime Time?

American journal of clinical dermatology, 2021-07, Vol.22 (4), p.511-522

2021

Volltextzugriff (PDF)

New Therapies in Advanced Cutaneous Malignancies

1st Edition 2021, 2021

Volltextzugriff (PDF)

Cobimetinib in malignant melanoma: how to MEK an impact on long-term survival

Future oncology (London, England), 2019-03, Vol.15 (9), p.967-977

2019

Volltextzugriff (PDF)

First-line encorafenib plus binimetinib and pembrolizumab for advanced BRAF V600-mutant melanoma: Safety lead-in results from the randomized phase III STARBOARD study

European journal of cancer (1990), 2024-12, Vol.213, p.115070, Article 115070

2024

Volltextzugriff (PDF)

Rationale for New Checkpoint Inhibitor Combinations in Melanoma Therapy

American journal of clinical dermatology, 2017-10, Vol.18 (5), p.597-611

2017

Volltextzugriff (PDF)

The prognostic role of mitotic rate in cutaneous malignant melanoma: Evidence from a multicenter study on behalf of the Italian Melanoma Intergroup

Cancer, 2023-08, Vol.129 (15), p.2331-2340

2023

Volltextzugriff (PDF)

Cutaneous toxicities of BRAF inhibitors: Clinical and pathological challenges and call to action

Critical reviews in oncology/hematology, 2013-11, Vol.88 (2), p.318-337

2013

Volltextzugriff (PDF)

Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial

European journal of cancer (1990), 2024-03, Vol.199, p.113531-113531, Article 113531

2024

Volltextzugriff (PDF)

1 – 25 von 94

Suche als RSS-Feed

Aktive Filter

ThemaFemale

ThemaMelanoma

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(84)
Mit Volltextzugriff
(85)

Publikationsform

Sprache

Englisch
(94)

Erscheinungsjahr

n.n

Thema

14 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis

Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma

Targeting the PD1/PD-L1 axis in melanoma: Biological rationale, clinical challenges and opportunities

Wnt/β-catenin signaling in melanoma: preclinical rationale and novel therapeutic insights

Rational combination of cancer immunotherapy in melanoma

Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial

Dedifferentiated melanomas: Morpho-phenotypic profile, genetic reprogramming and clinical implications

Safety and efficacy evaluation of encorafenib plus binimetinib for the treatment of advanced BRAF-mutant melanoma patients

Nras in melanoma: Targeting the undruggable target

Tissue prognostic biomarkers in primary cutaneous melanoma

Targeting BRAF in melanoma: Biological and clinical challenges

Molecular Pathways in Melanomagenesis: What We Learned from Next-Generation Sequencing Approaches

Targeting inflamed and non-inflamed melanomas: biological background and clinical challenges

Molecular Profiling and Novel Therapeutic Strategies for Mucosal Melanoma: A Comprehensive Review

Pathology of Immunotherapy-induced Responses in Cutaneous Melanoma: Current Evidences and Future Perspectives

Impact of second opinion pathology review in the diagnosis and management of atypical melanocytic lesions: A prospective study of the Italian Melanoma Intergroup (IMI) and EORTC Melanoma Group

Adjuvant Treatment of Melanoma: Recent Developments and Future Perspectives

Impact of Circulating and Tissue Biomarkers in Adjuvant and Neoadjuvant Therapy for High-Risk Melanoma: Ready for Prime Time?

New Therapies in Advanced Cutaneous Malignancies

Cobimetinib in malignant melanoma: how to MEK an impact on long-term survival

First-line encorafenib plus binimetinib and pembrolizumab for advanced BRAF V600-mutant melanoma: Safety lead-in results from the randomized phase III STARBOARD study

Rationale for New Checkpoint Inhibitor Combinations in Melanoma Therapy

The prognostic role of mitotic rate in cutaneous malignant melanoma: Evidence from a multicenter study on behalf of the Italian Melanoma Intergroup

Cutaneous toxicities of BRAF inhibitors: Clinical and pathological challenges and call to action

Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial

Aktive Filter

Suchergebnisse filtern